Menu

Biocartis submits 510(k) file with US FDA for Idylla™ platform

Submission done in parallel with 510(k) submission of Janssen Idylla™ Respiratory (IFV-RSV) Panel Test by Janssen Diagnostics
Non-regulated information

CE-marking Idylla™ NRAS-BRAF Mutation Test completes offering of metastatic colorectal cancer tests for clinical use on Idylla™ platform

Non-regulated information

Biocartis launches second liquid biopsy assay

Assay co-developed with Merck for detection of KRAS mutations, operating directly on 1 ml blood plasma
Non-regulated information

Biocartis receives EUR 1.4m grant to support development of its rapid NGS Prep Panels

Non-regulated information

Biocartis receives EUR 2.5m strategic grant from Flemish government to support manufacturing capacity expansion

Minister Muyters, Flemish Minister of Work, Economy, Innovation and Sports visits Biocartis on 18 October 2016 to announce the grant
Non-regulated information

AstraZeneca Comparative Study confirms Best-In-Class Status of Idylla™ KRAS Mutation Detection Technology

Non-regulated information

Three Idylla™ Test Performance Studies to be presented at Esmo Oncology Conference

Non-regulated information

Biocartis launches advanced EGFR Mutation Assay detecting over 50 mutations

Important addition to Biocartis’ core oncology menu now covering most known and used oncology biomarkers
Non-regulated information

Idylla™ Ebola Virus Triage Test Granted Emergency Use Authorization by U.S. FDA

Non-regulated information

Study demonstrating Biocartis’ BRAF liquid biopsy assay...

Test can predict therapy response over the course of the cancer treatment
Non-regulated information